-
Innovation Ranking
NewInnovation Ranking – Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc (Madrigal), formerly Synta Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel drugs for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, resmetirom (MGL-3196), is a proprietary, liver-directed, selective thyroid hormone receptor beta (THR-beta) agonist that can potentially help treat several diseases with high unmet medical need. The company is developing resmetirom for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), associated dyslipidemias and familial hypercholesterolemia...
-
Product Insights
NewNet Present Value Model: Madrigal Pharmaceuticals Inc’s Resmetirom
Empower your strategies with our Net Present Value Model: Madrigal Pharmaceuticals Inc's Resmetirom report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Madrigal Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Madrigal Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: GSK plc’s Men ABCWY
Empower your strategies with our Net Present Value Model: GSK plc's Men ABCWY report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resmetirom in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resmetirom in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resmetirom in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Resmetirom (MGL-3196,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NG-641 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NG-641 in Colorectal Cancer Drug Details: NG-641 is under development for the treatment of metastatic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resmetirom in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resmetirom in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resmetirom in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Resmetirom (MGL-3196, VIA-3196) is...